Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study

This publication has 19 references indexed in Scilit:

• Direct Comparison of Measures of Endurance, Mobility, and Joint Function During Enzyme-Replacement Therapy of Mucopolysaccharidosis VI (Maroteaux-Lamy Syndrome): Results After 48 Weeks in a Phase 2 Open-Label Clinical Study of Recombinant Human N-Acetylgalactosamine 4-Sulfatase
  Pediatrics, 2005
• Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)
  American Journal of Medical Genetics Part A, 2005
• Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)
  The Journal of Pediatrics, 2004
• Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human α-L-iduronidase (laronidase)
  The Journal of Pediatrics, 2004
• Replacement therapy in Mucopolysaccharidosis type VI: advantages of early onset of therapy
  Molecular Genetics and Metabolism, 2003
• Enzyme replacement therapy in a feline model of Maroteaux-Lamy syndrome.
  Journal of Clinical Investigation, 1996
• Prediction of Mortality and Morbidity With a 6-Minute Walk Test in Patients With Left Ventricular Dysfunction
  JAMA, 1993
• Attempted enzyme replacement using human amnion membane implantations in mucopolysaccharidoses
  Journal of Inherited Metabolic Disease, 1991
• Stair Climbing as an Indicator of Pulmonary Function
  Chest, 1987
• Bone-Marrow Transplantation in the Maroteaux–Lamy Syndrome (Mucopolysaccharidosis Type VI)
  New England Journal of Medicine, 1984